SFMG Wealth Advisors’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$279K Sell
1,414
-76
-5% -$14.7K 0.02% 257
2025
Q4
$274K Buy
1,490
+94
+7% +$16.5K 0.02% 254
2025
Q3
$214K Sell
1,396
-104
-7% -$15.7K 0.01% 273
2025
Q2
$210K Sell
1,500
-42
-3% -$5.89K 0.02% 252
2025
Q1
$227K Buy
+1,542
New +$223K 0.02% 243
2024
Q4
Sell
-1,458
Closed -$227K 275
2024
Q3
$227K Buy
1,458
+50
+4% +$8.07K 0.02% 230
2024
Q2
$220K Sell
1,408
-495
-26% -$74.5K 0.02% 232
2024
Q1
$258K Buy
1,903
+25
+1% +$3.31K 0.02% 217
2023
Q4
$253K Sell
1,878
-9
-0.5% -$1.17K 0.02% 212
2023
Q3
$256K Buy
1,887
+12
+0.6% +$1.64K 0.03% 195
2023
Q2
$268K Sell
1,875
-281
-13% -$41.3K 0.03% 189
2023
Q1
$299K Buy
2,156
+90
+4% +$12.1K 0.03% 179
2022
Q4
$280K Sell
2,066
-88
-4% -$11K 0.03% 187
2022
Q3
$237K Buy
2,154
+72
+3% +$9.13K 0.03% 197
2022
Q2
$275K Hold
2,082
0.03% 189
2022
Q1
$276K Sell
2,082
-153
-7% -$18.3K 0.03% 214
2021
Q4
$260K Sell
2,235
-938
-30% -$110K 0.03% 223
2021
Q3
$381K Buy
3,173
+677
+27% +$78.8K 0.04% 170
2021
Q2
$299K Hold
2,496
0.03% 196
2021
Q1
$248K Sell
2,496
-319
-11% -$32.1K 0.03% 206
2020
Q4
$281K Buy
2,815
+278
+11% +$29.4K 0.04% 172
2020
Q3
$278K Buy
2,537
+599
+31% +$66.6K 0.04% 142
2020
Q2
$205K Buy
+1,938
New +$200K 0.03% 150

Other funds holding AZN

SFMG Wealth Advisors's AZN Position: Q1 2026 in Review

SFMG Wealth Advisors reduced its AstraZeneca (AZN) stake by 5.1% in Q1 2026, selling an estimated $14.7K and leaving 1,414 shares worth $279K. The position accounts for 0.02% of the portfolio, ranked #257.

SFMG Wealth Advisors first reported a position in AZN in Q2 2020 and has held it in 23 quarters since. The position peaked at $381K in Q3 2021. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • SFMG Wealth Advisors held 1,414 shares of AstraZeneca worth $279K as of Q1 2026.
  • SFMG Wealth Advisors sold 76 AstraZeneca shares in Q1 2026, an estimated $14.7K.
  • AstraZeneca made up 0.02% of SFMG Wealth Advisors's portfolio in Q1 2026, its #257 holding.
  • SFMG Wealth Advisors first reported a position in AstraZeneca in Q2 2020 and has held it in 23 quarters since.
  • SFMG Wealth Advisors's AstraZeneca position peaked at $381K in Q3 2021.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on SFMG Wealth Advisors's 13F filing for Q1 2026, filed 12 May 2026.